Cargando…
New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review
BACKGROUND: Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. OBJECTIVES: To describe...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559550/ https://www.ncbi.nlm.nih.gov/pubmed/36229799 http://dx.doi.org/10.1186/s12876-022-02507-3 |
_version_ | 1784807662795358208 |
---|---|
author | Alhumaid, Saad Al Mutair, Abbas Rabaan, Ali A. ALShakhs, Fatemah M. Choudhary, Om Prakash Yong, Shin Jie Nainu, Firzan Khan, Amjad Muhammad, Javed Alhelal, Fadil Al Khamees, Mohammed Hussain Alsouaib, Hussain Ahmed Al Majhad, Ahmed Salman AL-Tarfi, Hassan Redha ALyasin, Ali Hussain Alatiyyah, Yaqoub Yousef Alsultan, Ali Ahmed Alessa, Mohammed Essa Alessa, Mustafa Essa Alissa, Mohammed Ahmed Alsayegh, Emad Hassan Alshakhs, Hassan N. Al Samaeel, Haidar Abdullah AlShayeb, Rugayah Ahmed Alnami, Dalal Ahmed Alhassan, Hussain Ali Alabdullah, Abdulaziz Abdullah Alhmed, Ayat Hussain AlDera, Faisal Hussain Hajissa, Khalid Al-Tawfiq, Jaffar A. Al-Omari, Awad |
author_facet | Alhumaid, Saad Al Mutair, Abbas Rabaan, Ali A. ALShakhs, Fatemah M. Choudhary, Om Prakash Yong, Shin Jie Nainu, Firzan Khan, Amjad Muhammad, Javed Alhelal, Fadil Al Khamees, Mohammed Hussain Alsouaib, Hussain Ahmed Al Majhad, Ahmed Salman AL-Tarfi, Hassan Redha ALyasin, Ali Hussain Alatiyyah, Yaqoub Yousef Alsultan, Ali Ahmed Alessa, Mohammed Essa Alessa, Mustafa Essa Alissa, Mohammed Ahmed Alsayegh, Emad Hassan Alshakhs, Hassan N. Al Samaeel, Haidar Abdullah AlShayeb, Rugayah Ahmed Alnami, Dalal Ahmed Alhassan, Hussain Ali Alabdullah, Abdulaziz Abdullah Alhmed, Ayat Hussain AlDera, Faisal Hussain Hajissa, Khalid Al-Tawfiq, Jaffar A. Al-Omari, Awad |
author_sort | Alhumaid, Saad |
collection | PubMed |
description | BACKGROUND: Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. OBJECTIVES: To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination. METHODS: For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction. RESULTS: Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy. CONCLUSION: Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks. |
format | Online Article Text |
id | pubmed-9559550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95595502022-10-14 New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review Alhumaid, Saad Al Mutair, Abbas Rabaan, Ali A. ALShakhs, Fatemah M. Choudhary, Om Prakash Yong, Shin Jie Nainu, Firzan Khan, Amjad Muhammad, Javed Alhelal, Fadil Al Khamees, Mohammed Hussain Alsouaib, Hussain Ahmed Al Majhad, Ahmed Salman AL-Tarfi, Hassan Redha ALyasin, Ali Hussain Alatiyyah, Yaqoub Yousef Alsultan, Ali Ahmed Alessa, Mohammed Essa Alessa, Mustafa Essa Alissa, Mohammed Ahmed Alsayegh, Emad Hassan Alshakhs, Hassan N. Al Samaeel, Haidar Abdullah AlShayeb, Rugayah Ahmed Alnami, Dalal Ahmed Alhassan, Hussain Ali Alabdullah, Abdulaziz Abdullah Alhmed, Ayat Hussain AlDera, Faisal Hussain Hajissa, Khalid Al-Tawfiq, Jaffar A. Al-Omari, Awad BMC Gastroenterol Research BACKGROUND: Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. OBJECTIVES: To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination. METHODS: For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction. RESULTS: Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy. CONCLUSION: Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks. BioMed Central 2022-10-13 /pmc/articles/PMC9559550/ /pubmed/36229799 http://dx.doi.org/10.1186/s12876-022-02507-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Alhumaid, Saad Al Mutair, Abbas Rabaan, Ali A. ALShakhs, Fatemah M. Choudhary, Om Prakash Yong, Shin Jie Nainu, Firzan Khan, Amjad Muhammad, Javed Alhelal, Fadil Al Khamees, Mohammed Hussain Alsouaib, Hussain Ahmed Al Majhad, Ahmed Salman AL-Tarfi, Hassan Redha ALyasin, Ali Hussain Alatiyyah, Yaqoub Yousef Alsultan, Ali Ahmed Alessa, Mohammed Essa Alessa, Mustafa Essa Alissa, Mohammed Ahmed Alsayegh, Emad Hassan Alshakhs, Hassan N. Al Samaeel, Haidar Abdullah AlShayeb, Rugayah Ahmed Alnami, Dalal Ahmed Alhassan, Hussain Ali Alabdullah, Abdulaziz Abdullah Alhmed, Ayat Hussain AlDera, Faisal Hussain Hajissa, Khalid Al-Tawfiq, Jaffar A. Al-Omari, Awad New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review |
title | New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review |
title_full | New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review |
title_fullStr | New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review |
title_full_unstemmed | New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review |
title_short | New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review |
title_sort | new-onset and relapsed liver diseases following covid-19 vaccination: a systematic review |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559550/ https://www.ncbi.nlm.nih.gov/pubmed/36229799 http://dx.doi.org/10.1186/s12876-022-02507-3 |
work_keys_str_mv | AT alhumaidsaad newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT almutairabbas newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT rabaanalia newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alshakhsfatemahm newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT choudharyomprakash newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT yongshinjie newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT nainufirzan newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT khanamjad newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT muhammadjaved newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alhelalfadil newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alkhameesmohammedhussain newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alsouaibhussainahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT almajhadahmedsalman newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT altarfihassanredha newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alyasinalihussain newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alatiyyahyaqoubyousef newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alsultanaliahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alessamohammedessa newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alessamustafaessa newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alissamohammedahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alsayeghemadhassan newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alshakhshassann newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alsamaeelhaidarabdullah newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alshayebrugayahahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alnamidalalahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alhassanhussainali newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alabdullahabdulazizabdullah newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alhmedayathussain newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alderafaisalhussain newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT hajissakhalid newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT altawfiqjaffara newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview AT alomariawad newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview |